Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06152146
NCT06152146WithdrawnNot Applicable

Randomized Controlled Trial of Low Intensity Shockwaves Therapy for the Treatment of Post-Radical Prostatectomy Erectile Dysfunction. SHARP-ED TRIAL

University of Miami2 sites in 1 countryStarted: July 8, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
2
Primary Endpoint
Change in number of participants reporting on Penetrative Intercourse
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Research study designed to learn about and compare Shockwave therapy (SWT) vs placebo (no shockwaves) treatment in men with moderate to severe erectile dysfunction (ED) after Radical Prostatectomy

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
40 Years to 75 Years (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Be willing and able to provide informed consent.
  • •Be ≥ 40 and ≤ 75 years of age (inclusive).
  • •Undergo radical prostatectomy for prostate cancer (nerve sparing or non-nerve sparing without neoadjuvant chemotherapy or radiation therapy.)
  • •Be at least six weeks post radical prostatectomy.
  • •Be in a stable sexual relationship for over 3 months prior to enrollment.
  • •Have testosterone level of 300-1000 ng/dL within 1 month prior to enrollment.
  • •Have an HbA1c level ≤ 7% within 3 months prior to enrollment.
  • •Have undetectable PSA value at the time of enrollment

Exclusion Criteria

  • •Be currently participating in a clinical trial or have recently received an investigational therapy within the past 30 days that may interfere with the results of this study.
  • •Be under judicial protection (prison or custody).
  • •Be an adult under guardianship.
  • •Refuse to sign the informed consent.
  • •Have evidence of venous leak prior to surgery or use of PDE5i prior to surgery
  • •Have past radiation therapy of the pelvic region or hormonal therapy with androgen deprivation within 12 months prior to enrollment.
  • •Be recovering from any cancer within 12 months prior to enrollment (other than prostate cancer)
  • •Have Neurological disease such as Alzheimer's or Parkinson's disease which affects erectile function (at the discretion of the investigator).
  • •Have a Psychiatric diagnosis or medications such as antidepressants, anxiolytic, antipsychotic that affects erectile function or any other medications (at the discretion of the investigator).
  • •Have an anatomical malformation of the penis, including Peyronie's disease.
  • •Have testosterone level <300 or >1000 ng/dL within 1 month prior to enrollment.
  • •Be using blood thinners with international normalized ratio (INR) to be >
  • •Have received shockwave therapy for at least 6 months before enrollment.
  • •Have detectable PSA value after the radical prostatectomy.
  • •Require radiation therapy after radical prostatectomy.
  • •Require hormonal therapy after radical prostatectomy.

Outcomes

Primary Outcomes

Change in number of participants reporting on Penetrative Intercourse

Time Frame: Baseline to 6 months and Baseline to 12 months.

Number of participants reporting the ability to have penetrative intercourse with or without PDE5i but without the use of intracavernosal injections was chosen as the primary clinical efficacy assessment tool in this study.

Secondary Outcomes

  • Change in GAQ- Global Assessment Questions(Baseline to 6 months and Baseline to 12 months.)
  • Change in Penile blood flow (Penile Duplex Ultrasound) measured in centimeters per second (cm/sec)(Baseline to 12 months.)
  • Change in IIEF-EF Scores(Baseline to 6 months and Baseline to 12 months.)
  • Change in SEP- Sexual Encounter Profile: Questions 2 and 3(Baseline to 6 months and Baseline to 12 months.)
  • Change in EHS- Erection Hardness Score(Baseline to 6 months and Baseline to 12 months.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Russell Saltzman

Regulatory Specialist

University of Miami

Study Sites (2)

Loading locations...

Similar Trials

Terminated
Not Applicable
Low Intensity Shockwaves Therapy for the Treatment of Erectile Dysfunction. 12- Month Follow-UpErectile Dysfunction
NCT03670628University of Miami23
Unknown
Phase 2
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED TreatmentErectile Dysfunction
NCT05366504Institute for the Study of Urological Diseases, Greece60
Completed
Not Applicable
Low-intensity Shockwaves Therapy for the Treatment of Patients With Moderate Vasculogenic Erectile DysfunctionErectile Dysfunction
NCT03518983Institute for the Study of Urological Diseases, Greece70
Completed
Not Applicable
Low-intensity Shockwave Therapy for Non-bacterial Prostatitis/Pelvic Pain SyndromeChronic Prostatitis
NCT03543761Institute for the Study of Urological Diseases, Greece45
Completed
Not Applicable
Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass GraftingHeart Failure PatientsCardiac Ischemia
NCT03859466Medical University Innsbruck63